title: Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Marcus
authors.initials: M
authors.lastname: Maurer
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Schütz
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Karsten
authors.initials: K
authors.lastname: Weller
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Nicole
authors.initials: N
authors.lastname: Schoepke
authors.affiliation: Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Adriane
authors.initials: A
authors.lastname: Peveling-Oberhag
authors.affiliation: Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Staubach
authors.affiliation: Department of Dermatology, University Medical Center Freiburg, Freiburg, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Müller
authors.affiliation: Department of Dermatology, University Medical Center Freiburg, Freiburg, Germany; Department of Dermatology and Allergology, University Medical Center Giessen and Marburg, Campus Giessen, Justus-Liebig University, Giessen, Germany.
authors.forename: Thilo
authors.initials: T
authors.lastname: Jakob
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: martin.metz@charite.de.
authors.forename: Martin
authors.initials: M
authors.lastname: Metz
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D006633:Histamine Antagonists; D000069444:Omalizumab